Gene · 6138
RPL15: ribosomal protein L15
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPL15: ribosomal protein L15. Genes, record 6138. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6138
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P61313 | Large ribosomal subunit protein eL15 | 204 | 175 | Ensembl, GeneID, HGNC |
Source UniProt
Patents61
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 61980 | P61313 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 61981 | P61313 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 61983 | P61313 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 61984 | P61313 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 61987 | P61313 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 4611 | P61313 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4846 | P61313 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 4611 | P61313 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4846 | P61313 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73951 | P61313 | Espacenet |
1 to 10 of 61
See all 61 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATALUREN | CHEMBL256997 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| CITATUZUMAB BOGATOX | CHEMBL1743000 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| CYCLOHEXIMIDE | CHEMBL123292 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| DORLIMOMAB ARITOX | CHEMBL2109124 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ELX-02 | CHEMBL4297744 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| MT-3724 | CHEMBL4297789 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TAPLITUMOMAB PAPTOX | CHEMBL2107890 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TELIMOMAB ARITOX | CHEMBL2108790 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ZOLIMOMAB ARITOX | CHEMBL2108785 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
Trials38
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07523581 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT05448755 | ELX-02 | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT04336826 | ATALUREN | PHASE2 | 2024-04-01 | ClinicalTrials.gov |
| NCT04135495 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04126473 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04117880 | ATALUREN | PHASE2 | ClinicalTrials.gov | |
| NCT04069260 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04014530 | ATALUREN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03796637 | ATALUREN | PHASE2 | 2022-04-05 | ClinicalTrials.gov |
| NCT03645395 | MT-3724 | PHASE2 | 2022-08-16 | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsNIH grants677
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPL15 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 3 | 2025 |
| P30CA072720 | Cancer Center Support Grant | 3 | 2025 |
| P30CA142543 | UT Southwestern Medical Center Simmons Comprehensive Cancer Center | 3 | 2025 |
| R01DK103794 | Systematic Genetic Dissection of Human Erythropoiesis | 3 | 2025 |
| RM1HG009490 | Center for Genomic Editing and Recording: Development and Application of Next-Generation Genome and Epigenome Editing Methods to Advance the Study and Treatment of Human Disease | 3 | 2025 |
| K12CA087723 | Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology | 2 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 2 | 2025 |
| P20GM121176 | Autophagy, Inflammation and Metabolism (AIM) in Disease Center - Phase 2. | 2 | 2025 |
| P20GM121293 | Center for Translational Pediatric Research | 2 | 2025 |
1 to 10 of 677Source NIH's project files
See all 677 nih grantsPapers806
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Single-cell transcriptomics combined with Mendelian randomization reveals the pivotal role of WDR83OS in clear cell renal cell carcinoma: An observational and bioinformatic study. | Medicine (Baltimore) | 2026 | 42760660 | PubTator, text mining | PubMed |
| The loss of function of a C2H2 zinc finger protein alleviates its inhibitory effect on LsRPL15, causing dense red spots in lettuce. | Plant Physiol | 2026 | 42612177 | PubTator, text mining | PubMed |
| Fully Complementary Interactions Between LmiRNA and mRNA of Human Genes. | Curr Issues Mol Biol | 2026 | 42510906 | PubTator, text mining | PubMed |
| Association between omeprazole and memory impairment: Insights from NHANES data analysis and network pharmacology studies. | J Alzheimers Dis | 2026 | 41879275 | PubTator, text mining | PubMed |
| Maternal opioid use disorder and hepatitis C infection in pregnancy reshape the peripheral immune landscape at term. | EBioMedicine | 2026 | 41849830 | PubTator, text mining | PubMed |
| Neurons with granulovacuolar degeneration bodies are resilient to tau-induced protein synthesis impairment. | Sci Adv | 2026 | 41790889 | PubTator, text mining | PubMed |
| Identification of multigene predictors of prognosis in patients with ovarian cancer. | iScience | 2026 | 41767263 | PubTator, text mining | PubMed |
| Decoding the role of RPL38 in lung adenocarcinoma: a multi-omics approach. | Front Immunol | 2026 | 41766901 | PubTator, text mining | PubMed |
| PROTAC-based protein degradation: a window of opportunity for melanoma therapy. | J Biomed Sci | 2026 | 41761284 | PubTator, text mining | PubMed |
| Tissue-Specific Multi-Omics Integration Demonstrates Molecular Signatures Connecting Obesity to Immune Vulnerability. | Metabolites | 2026 | 41745578 | PubTator, text mining | PubMed |
1 to 10 of 806
See all 806 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6138
GET https://conductscience.org/api/genes/v1/6138/patents?page=2